Burning Rock Biotech Limited BNR · NASDAQ
$12.90 -17.31% (-$2.70)
Summary
42 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: ¥419.3M against ¥45.1M.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 1.4% a year over the last 3 years.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (CNY)
Diluted EPS (CNY)
Revenue grew by 4.6% a year over 5 years. Over the last 3 years it fell by 1.4% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of ¥68.0M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Service 59%
- Product 41%
By region
- CHINA 99%
- UNITED STATES 1.1%
Service brings in 59% of revenue. Product grew fastest, by 0.9% a year.
Segments in detail